Display options
Cite
Caleca L, Colombo M, van Overeem Hansen T, et al. GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes. Cancers (Basel). 2019;11(2)doi: 10.3390/cancers11020151.
Caleca, L., Colombo, M., van Overeem Hansen, T., Lázaro, C., Manoukian, S., Parsons, M. T., Spurdle, A. B., & Radice, P. (2019). GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes. Cancers, 11(2), . https://doi.org/10.3390/cancers11020151
Caleca, Laura, et al. "GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes." Cancers vol. 11,2 (2019). doi: https://doi.org/10.3390/cancers11020151
Caleca L, Colombo M, van Overeem Hansen T, Lázaro C, Manoukian S, Parsons MT, Spurdle AB, Radice P. GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes. Cancers (Basel). 2019 Jan 28;11(2). doi: 10.3390/cancers11020151. PMID: 30696104; PMCID: PMC6406614.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Jan 28;11(2). doi: 10.3390/cancers11020151.

GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes.

Cancers

Laura Caleca, Mara Colombo, Thomas van Overeem Hansen, Conxi Lázaro, Siranoush Manoukian, Michael T Parsons, Amanda B Spurdle, Paolo Radice

Affiliations

  1. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. [email protected].
  2. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. [email protected].
  3. Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark. [email protected].
  4. Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark. [email protected].
  5. Hereditary Cancer Program, Catalan Institute of Oncology. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, 08900 Barcelona, Spain. [email protected].
  6. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain. [email protected].
  7. Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. [email protected].
  8. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia. [email protected].
  9. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia. [email protected].
  10. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. [email protected].

PMID: 30696104 PMCID: PMC6406614 DOI: 10.3390/cancers11020151

Abstract

Genetic testing for

Keywords: BRCA1; BRCA2; functional assays; hereditary breast/ovarian cancer; protein-protein interaction; variant of uncertain significance

Conflict of interest statement

P.R. was scientific coordinator of a course on the classification of BRCA gene allele variants sponsored by AstraZeneca (Milan, June 2018).

References

  1. Acta Crystallogr D Biol Crystallogr. 1998 Nov 1;54(Pt 6 Pt 1):1078-84 - PubMed
  2. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5134-9 - PubMed
  3. Cancer Res. 2001 Jun 15;61(12):4842-50 - PubMed
  4. Nat Struct Biol. 2001 Oct;8(10):833-7 - PubMed
  5. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12078-83 - PubMed
  6. Cell. 2002 Jan 25;108(2):171-82 - PubMed
  7. J Biol Chem. 2002 Jun 14;277(24):22085-92 - PubMed
  8. Science. 2002 Sep 13;297(5588):1837-48 - PubMed
  9. EMBO J. 2002 Dec 16;21(24):6755-62 - PubMed
  10. J Biol Chem. 2003 Sep 12;278(37):34743-6 - PubMed
  11. Hum Mol Genet. 2003 Sep 1;12(17):2121-31 - PubMed
  12. Am J Hum Genet. 2004 Oct;75(4):535-44 - PubMed
  13. EMBO Rep. 2004 Oct;5(10):989-93 - PubMed
  14. Cancer Res. 2005 Jan 15;65(2):417-26 - PubMed
  15. J Biol Chem. 2005 Jun 10;280(23):21854-7 - PubMed
  16. Nat Methods. 2004 Dec;1(3):255-62 - PubMed
  17. Oncogene. 2006 Feb 23;25(8):1186-94 - PubMed
  18. Hum Mol Genet. 2006 Feb 15;15(4):599-606 - PubMed
  19. Mol Cell. 2006 Jun 23;22(6):719-29 - PubMed
  20. Oncogene. 2006 Sep 25;25(43):5864-74 - PubMed
  21. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6614-9 - PubMed
  22. Science. 2007 May 25;316(5828):1202-5 - PubMed
  23. Am J Hum Genet. 2007 Nov;81(5):873-83 - PubMed
  24. Cell Div. 2008 Jan 07;3:1 - PubMed
  25. J Clin Oncol. 2008 Apr 1;26(10):1657-63 - PubMed
  26. Cancer Res. 2008 May 1;68(9):3523-31 - PubMed
  27. Mol Biosyst. 2008 Jun;4(6):599-605 - PubMed
  28. J Clin Oncol. 2008 Nov 20;26(33):5393-400 - PubMed
  29. Hum Mutat. 2008 Nov;29(11):1282-91 - PubMed
  30. Hum Mutat. 2008 Nov;29(11):1342-54 - PubMed
  31. Breast Cancer Res Treat. 2010 Feb;119(3):737-43 - PubMed
  32. Cancer Res. 2010 Feb 1;70(3):988-95 - PubMed
  33. Curr Opin Genet Dev. 2010 Jun;20(3):315-23 - PubMed
  34. Hum Mutat. 2010 Jun;31(6):E1484-505 - PubMed
  35. Radiat Res. 2010 Jul;174(1):1-13 - PubMed
  36. Fam Cancer. 2011 Jun;10(2):207-12 - PubMed
  37. Blood. 2011 Sep 1;118(9):2430-42 - PubMed
  38. Oncogene. 2012 Feb 9;31(6):799-804 - PubMed
  39. Hum Mutat. 2011 Dec;32(12):1470-80 - PubMed
  40. Hum Mutat. 2012 Jan;33(1):8-21 - PubMed
  41. Science. 2011 Oct 28;334(6055):525-8 - PubMed
  42. Cancer Cell. 2011 Dec 13;20(6):797-809 - PubMed
  43. Nat Rev Cancer. 2011 Dec 23;12(1):68-78 - PubMed
  44. EMBO J. 2012 Mar 7;31(5):1160-76 - PubMed
  45. Hum Mutat. 2012 Aug;33(8):1228-38 - PubMed
  46. Hum Mutat. 2012 Nov;33(11):1526-37 - PubMed
  47. Cancer Res. 2013 Jan 1;73(1):265-75 - PubMed
  48. Hum Mutat. 2013 Mar;34(3):439-45 - PubMed
  49. J Natl Cancer Inst. 2013 Jun 5;105(11):812-22 - PubMed
  50. Cancer Discov. 2013 Oct;3(10):1142-55 - PubMed
  51. Nat Struct Mol Biol. 2013 Oct;20(10):1191-8 - PubMed
  52. Clin Genet. 2013 Nov;84(5):407-14 - PubMed
  53. Front Oncol. 2013 Sep 11;3:228 - PubMed
  54. Sci Rep. 2013 Oct 04;3:2854 - PubMed
  55. Hum Mutat. 2014 Feb;35(2):151-64 - PubMed
  56. PLoS One. 2014 Jan 28;9(1):e86836 - PubMed
  57. PLoS One. 2014 Feb 06;9(2):e86924 - PubMed
  58. Hum Mol Genet. 2014 Jul 15;23(14):3666-80 - PubMed
  59. J Clin Oncol. 2014 Jul 1;32(19):2001-9 - PubMed
  60. Hum Mutat. 2014 Nov;35(11):1382-91 - PubMed
  61. Genetics. 2015 Jun;200(2):413-22 - PubMed
  62. Eur J Intern Med. 2016 Jul;32:65-71 - PubMed
  63. PLoS Genet. 2016 Jun 06;12(6):e1006096 - PubMed
  64. Am J Hum Genet. 2018 Feb 1;102(2):233-248 - PubMed
  65. Hum Mutat. 2018 May;39(5):593-620 - PubMed
  66. Genet Med. 2018 Jul 10;:null - PubMed
  67. Nature. 2018 Oct;562(7726):217-222 - PubMed
  68. J Med Genet. 2018 Dec 22;:null - PubMed
  69. Nat Genet. 1996 Dec;14(4):430-40 - PubMed
  70. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  71. Electrophoresis. 1997 Dec;18(15):2714-23 - PubMed
  72. J Biol Chem. 1998 Apr 3;273(14):7795-9 - PubMed

Publication Types

Grant support